Tilray Acquires Lyphe Group, Expands UK Medical Cannabis Reach

LONDON – Tilray Brands Inc. has acquired the Lyphe Group, a British operator of online medical Cannabis clinics and a digital pharmacy platform.

The deal adds a network that has treated more than 16,000 patients and dispensed roughly 150,000 units of medical Cannabis products in the United Kingdom. Lyphe’s services include virtual consultations with specialists and direct dispensing of prescribed Cannabis medicines, an area where patient demand has grown steadily since Britain legalized medical Cannabis in 2018.

Tilray, which already runs pharmaceutical-grade cultivation and production sites in Europe, described the purchase as a way to create its first fully integrated medical platform in the region. The combination links the company’s existing supply chain and CC Pharma distribution business with Lyphe’s clinical and patient-facing operations. Company officials expect the acquired business to contribute positively to earnings in 2027.

Rajnish Ohri, president of international operations at Tilray Brands, said the addition brings clinical expertise and a focus on patient care that complements the company’s manufacturing strengths. The move builds on Tilray’s earlier steps in the British market, including distribution agreements aimed at broadening access to both Cannabis-based and traditional prescription medicines.

The transaction comes as Tilray continues to balance its Cannabis roots with expansion into beverages. Just weeks earlier, the company completed the purchase of certain BrewDog assets in Britain and Ireland, part of a broader effort to scale its alcohol portfolio alongside medical Cannabis activities.

For the UK medical Cannabis sector, the acquisition highlights ongoing consolidation. Private clinics have filled much of the gap left by a relatively cautious National Health Service approach to prescriptions. Lyphe’s scale gives Tilray immediate reach into that private channel while positioning the company to benefit if regulators ease access rules further.